

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2020 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent

Editorial

- 1389** Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
T Dörner

Epidemiology

- 1393** Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases
D D Freites Nuñez, L Leon, A Mucientes, L Rodriguez-Rodriguez, J Font Urgelles, A Madrid García, J I Colomer, J A Jover, B Fernandez-Gutierrez, L Abasolo

Treatment

- 1400** Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
P Mease, C Charles-Schoeman, S Cohen, L Fallon, J Woolcott, H Yun, J Kremer, J Greenberg, W Malley, A Onofrei, K S Kanik, D Graham, C Wang, C Connell, H Valdez, M Hauben, E Hung, A Madsen, T V Jones, J R Curtis

Rheumatoid arthritis

- 1414** Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
S Plein, B Ethayiem, G Fent, S Horton, R B Dumitru, J Andrews, J P Greenwood, P Emery, E MA Hensor, P Baxter, S Pavitt, M H Buch
- 1423** EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries
R Meisters, P Putrik, S Ramiro, M Hifinger, A P Keszei, Y van Eijk-Hustings, A D Woolf, J S Smolen, T A Stamm, M Stoffer-Marx, T Uhlig, R H Moe, M de Wit, A Tafaj, V Mukuchyan, P Studenic, P Verschueren, R Shumnaieva, P Charalambous, J Vencovský, M Varvouni, M Kull, K Puolakekka, L Gossec, N Gobejishvili, J Detert, P Sidiropoulos, M Péntek, D Kane, C A Scirè, U Arad, D Andersone, M van de Laar, A van der Helm-van Mil, P Głuszeko, L Cunha-Miranda, F Berghea, N S Damjanov, M Tomšič, L Carmona, C Turesson, A Ciurea, S Shukurova, N Inanc, S MM Verstappen, A Boonen, Working group

- 1432** Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis
C Sharma, S Whittle, P D Haghighi, F Burstein, R Sa'adon, H I Keen

- 1438** Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis
Y-C Kwon, J Lim, S-Y Bang, E Ha, M Y Hwang, K Yoon, J-Y Choe, D-H Yoo, S-S Lee, J Lee, W T Chung, T-H Kim, Y-K Sung, S-C Shim, C-B Choi, J-B Jun, Y M Kang, J-M Shin, Y-K Lee, S-K Cho, B-J Kim, H-S Lee, K Kim, S-C Bae

- 1446** Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between *IL18RAP* expression and treatment response
S Cherlin, M J Lewis, D Plant, N Nair, K Goldmann, E Tzani, M R Barnes, P McKeigue, J H Barrett, C Pitzalis, A Barton, MATURA Consortium, H J Cordell

- 1453** Contrasting contributions of TNF from distinct cellular sources in arthritis
A Kruglov, M Druetskaya, D Schlienz, E Gorshkova, K Kurz, L Morawietz, S Nedospasov

Psoriatic arthritis

- 1460** Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study
J Xia, S-Y Xie, K-Q Liu, L Xu, P-P Zhao, S-R Gai, P-L Guan, J-Q Zhao, Y-P Zhu, L C Tsoi, P E Stuart, R P Nair, H-Q Yang, Y-T Liao, K Mao, M-C Qiu, Z-M Ying, B Hu, Z-H Yang, W-Y Bai, X-W Zhu, P-K Cong, J T Elder, Z-M Ye, B Wang, H-F Zheng

MORE CONTENTS ►



COPE

Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

Sjögren's syndrome

- 1468** Salivary gland epithelial cells from patients with Sjögren's syndrome induce B-lymphocyte survival and activation
E Rivière, J Pascaud, N Tchitchek, S Boudaoud, A Paoletti, B Ly, A Dupré, H Chen, A Thai, N Allaire, B Jagla, M Mingueneau, G Nocturne, X Mariette

Systemic sclerosis

- 1478** Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial
J R Seibold, T M Maher, K B Highland, S Assassi, A Azuma, L K Hummers, U Costabel, U von Wangenheim, V Kohlbrenner, M Gahlemann, M Alves, O Distler, on behalf of the SENSICIS trial investigators

IgG4 related disease

- 1485** Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
C Schmidkonz, S Rauber, A Atzinger, R Agarwal, T I Götz, A Soare, M Cordes, O Prante, C Bergmann, A Kleyer, P Ritt, S Maschauer, P Hennig, J Toms, M Köhner, B Manger, J H Stone, U Haberkorn, T Baeuerle, J H W Distler, A Agaimy, T Kuwert, G Schett, A Ramming

Autoinflammatory disorders

- 1492** Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the *NOD2* mutation
T Matsuda, N Kambe, Y Ueki, N Kanazawa, K Izawa, Y Honda, A Kawakami, S Takei, K Tonomura, M Inoue, H Kobayashi, I Okafuji, Y Sakurai, N Kato, Y Maruyama, Y Inoue, Y Otsuko, T Makino, S Okada, I Kobayashi, M Yashiro, S Ito, H Fujii, Y Kondo, N Okamoto, S Ito, N Iwata, U Kaneko, M Doi, J Hosokawa, O Ohara, M K Saito, R Nishikomori, PIDJ members in the JSIAD

Crystal arthropathies

- 1500** Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study
H B Hammer, L Karoliussen, L Terslev, E A Haavardsholm, T K Kvien, T Uhlig

- 1506** Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1 β activation on macrophages
F Renaudin, L Orliaguet, F Castelli, F Fenaille, A Prignon, F Alzaid, C Combes, A Delvaux, Y Adimy, M Cohen-Solal, P Richette, T Bardin, J-P Riveline, N Venteclef, F Lioté, L Campillo-Gimenez, H-K Ea

Letters

- 1515** Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?
P Ruscitti, O Berardicurti, A Barile, P Cipriani, Y Shoefeld, A Iagnocco, R Giacomelli
- 1516** Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive
M Greenwood, M Shipa, S-A Yeoh, E Roussou, D Mukerjee, M R Ehrenstein
- 1517** A pilot study of tofacitinib for refractory Behçet's syndrome
J Liu, Y Hou, L Sun, C Li, L Li, Y Zhao, X Zeng, F Zhang, W Zheng
- 1520** Standardisation of PR3-ANCA and MPO-ANCA: evaluation of certified reference materials
X Bossuyt, D Dillaerts, M Mahler, D Roggenbush, U Leinfelder, F Hammar, W Schlumberger, N Olschowka, J Damoiseaux

- 1522** Immune phenotyping of Erdheim-Chester disease through mass cytometry highlights decreased proportion of non-classical monocytes and increased proportion of Th17 cells
M Papo, A Corneau, F Cohen-Aubart, B Robin, J-F Emile, M Miyara, C Blanc, Z Amoura, O Hermine, J Haroche, T Trovati Maciel

Electronic pages

- e140** 'Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients'
M H Buch, A Melville, D G McGonagle
- e141** Response to: 'Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients' by Buch *et al*
F Humby, M Lewis, M J Townsend, C Pitzalis

- e142** DAPSA versus cDAPSA: Do we need to use CRP?
R S G Gonçalves, L M de Almeida Martins, H de Ataíde Mariz, A T Dantas, A L B P Duarte
- e143** Treat to target in PsA should focus on clinical measures. Response to: 'DAPSA versus cDAPSA: do we need to use CRP?' by Gonçalves *et al*
L J J van Mens, M G H van de Sande, A W R van Kuijk, D Baeten, L C Coates
- e144** Less antibiotics but no inferior effect for bacterial arthritis
J Tian, C Cheng, F Zhang
- e145** Response to: 'Less antibiotics but no inferior effect for bacterial arthritis' by Zhang *et al*
I Uçkay, E Gjika
- e146** Is it currently reasonable to offer short, 14-day antibiotic therapies after a surgical synovectomy in native joint septic arthritis?
G Coiffier, M Couderc, R Seror, G Bart, C Darrieutort-Laffite, B Le Goff
- e147** Response to: 'Is it currently reasonable to offer short 14-day antibiotic therapies after a surgical synovectomy in native joint septic arthritis?' by Coiffier *et al*
I Uçkay, A Gonzalez, E Gjika
- e148** Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter
N Sbeih, A Mathian, M Pineton de Chambrun, R Lhote, N Zahr, M Pha, F Cohen-Aubart, J Haroche, M Hié, S Jouffroy, N Benameur, H Devilliers, Z Amoura
- e149** Response to: 'Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter' by Sbeih *et al*
M Nikpour, M Huq, S Oon
- e150** Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations
G Orsolini, I E M Bultink, G Adami, A Fassio, O Viapiana, A Giollo, D Gatti, M Rossini
- e151** Response to: 'Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations' by Orsolini *et al*
A Fanouriakis, G Bertsias, D T Boumpas
- e152** Semiquantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?
I Cavazzana, M Fredi, F Franceschini
- e153** Response to: 'Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?' by Cavazzana *et al*
J Rönnelid, F Espinosa-Ortega, I E Lundberg